Novartis plans generic Lotrel launch

Share this article:
Novartis is planning an immediate US launch of generic Lotrelafter a federal judge declined to stop a rival’s copies from entering the market.

Yesterday the US District Court for the District of New Jersey vacated a restraining order against Teva Pharmaceuticals, freeing the company to resume shipping generic Lotrel. The Israeli firm received FDA approval for the generic in May and began shipping the drug before a temporary restraining order clamped new deliveries.

The New Jersey court also denied a Novartis motion for a preliminary injunction in an ongoing patent dispute between the companies.

Novartis vowed to launch an authorized copy through its Sandoz division but to continue pursuing its defense of intellectual property rights, as Lotrel has a US patent valid until 2017, the Swiss drug firm said.

Since the underlying patent challenge is unresolved, Teva’s Lotrel launch is at-risk, meaning it could face damages should the court rule in Novartis’ favor. A trial date has not been set.

Branded Lotrel had sales of $1.35 billion in 2006. Novartis said it is evaluating the potential impact of Teva’s actions on its full-year 2007 net sales.

Lotrel, which is only sold in the US, combines ACE inhibitor benazepril with calcium channel blocker amlodipine besylate, both of which are off-patent.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...

Xtandi duo boosts rep force for pre-chemo push

Xtandi duo boosts rep force for pre-chemo push

With its label extended to the pre-chemo setting, the prostate cancer drug is poised to reach a new group of urologists, and could upend J&J's Zytiga.